Rheumatoid factors in primary Sjögren's syndrome (pSS) use diverse V_H region **genes, the majority of which show no evidence of somatic hypermutation**

K. E. E. ELAGIB*¶, M. BØRRETZEN*, R. JONSSON‡, H. J. HAGA§, J. THOEN†, K. M. THOMPSON* &

J. B. NATVIG* **Institute of Immunology, Laboratory for Rheumatology Research and* †*Centre for Rheumatic Disease,*

The National Hospital, University of Oslo, Oslo, and ‡*Broegelmann Research Laboratory,* §*Division of Rheumatology,*

Medical Department B, Haukeland University Hospital, Bergen, Norway, and ¶*Institute of Nuclear Medicine and Molecular Biology, University of Gezira, Wad Medani, Sudan*

(Accepted for publication 25 March 1999)

SUMMARY

Rheumatoid factor (RF) is the most common autoantibody found in patients with Sjögren's syndrome (SS). To study the genetic origin and the mechanisms acting behind its generation we have characterized and sequenced the immunoglobulin V_H genes used by 10 IgM RF MoAbs derived from peripheral blood of six female patients with pSS. We compared the structure of the RF immunoglobulin V_H genes with those obtained previously from rheumatoid arthritis (RA) patients and healthy immunized donors (HID). V_H1 and V_H4 were each used by four RF clones, one clone was encoded by V_H3 family gene and one by V_H2 family gene. This distribution frequency was different from that observed in RA, where V_H3 was the dominant family, followed by V_H1 . Eight different germ-line (GL) genes encoded the clones and all of these genes were seen previously in RA and/or HID RF. Five clones rearranged to J_H6 , four rearranged to J_H4 and one to J_H5 , in contrast to RF from RA and HID, where J_H4 was most frequently used. D segment use and CDR3 structure were diverse. Interestingly, three out of four V_H4 clones used the GL gene DP-79 that was seen frequently in RA RF. The degree of somatic mutation in the pSS RF was very much lower than seen in RA and HID RF. All the pSS RF clones except three were in or very close to GL configuration. This indicates that there is little role for somatic hypermutation and a germinal centre reaction in the generation of RF from peripheral blood in pSS.

Keywords Sjögren's syndrome rheumatoid factor heavy chain variable region gene

INTRODUCTION

Sjögren's syndrome (SS) is an autoimmune disorder characterized by chronic inflammation of the exocrine glands, mainly the salivary and lachrymal glands leading to progressive destruction of these glands resulting in dryness of the mouth and conjunctiva (sicca syndrome) [1–3]. The disease can occur alone as pSS or it can be associated with other connective tissue diseases such as systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA), in which case it is referred to as secondary Sjögren's syndrome.

The main immunological feature of SS is mononuclear cell infiltration of the exocrine glands. Most of these cells are T cells $(75-85%)$ and B cells $(5-10%)$ [1,3]. A B cell activation results in hypergammaglobulinemia with elevated levels of circulating

E-mail: kamaleldin24@hotmail.com

autoantibodies seen are rheumatoid factors (RF), anti-Ro/SSA and anti-La/SSB [1–4]. RF is found in the serum and saliva of 60–80% of pSS patients [5,6]. RF is also found in other autoimmune conditions such as RA in about 70% of patients [7–9], SLE as well as healthy donors following certain infections and immunization [10–12], and finally as a monoclonal component (MC) in lymphoproliferative diseases. The structure and the genetic origins of RF are well character-

immune complexes and production of autoantibodies. Among the

ized in RA and healthy immunized donors (HID) [12–26]. IgM RF from RA are polyclonal and highly mutated with relatively high affinity. This suggests that they have been through a germinal centre reaction with affinity maturation. However, evidence from HID suggests that high-affinity RF B cells are eliminated by the mechanism of peripheral tolerance [18]. The aims of this study were to determine the genetic origin and the structure of RF from pSS patients. This might help to understand the mechanism behind generation of RF in pSS and to determine whether they show

Correspondence: Kamal Eldin Elsheikh Elagib , Institute of Immunology, Laboratory for Rheumatology Research, The National Hospital, Fr. Qvamsgt. 1, N-O172 Oslo, Norway.

evidence of being antigen-driven. For this purpose we derived 10 RF MoAbs from the peripheral blood of pSS patients using Epstein–Barr virus (EBV)/hybridoma technology. These MoAbs have diverse V gene usage. Most of the germ-line (GL) genes used were already identified in RF from RA but were used in different frequencies. Interestingly, seven out of 10 clones have very few somatic mutations, indicating that they have not been activated through a germinal centre reaction. Three other clones have moderate to high number of mutations, indicating a germinal centre process.

PATIENTS AND METHODS

Lymphocyte isolation and EBV transformation

Peripheral blood samples were obtained from six female patients with pSS aged between 36 and 77 years, fulfilling at least four of the preliminary European Classification Criteria for pSS [27]. They were either RF^+ by Waaler agglutination test and/or latex test measured by standard nephelometry assay [28]. Mononuclear cells were isolated by high-density gradient centrifugation using Lymphoprep (Nycomed, Oslo, Norway). The cells were incubated with 5 ml of supernatant from the B958 cell line containing EBV for 1 h at 37° C with 5% CO₂. After 1 h, Dulbecco's modified Eagle's medium (DMEM; Sigma, St Louis, MO) + Hams $F-12+10%$ fetal calf serum (FCS) was added to keep the number of cells at a concentration of 10^6 cells/ml, and the cells were incubated at 37° C and 5% CO₂. Phytohaemagglutinin (PHA; Sigma) was added after 24 h at a concentration of $10 \mu g/ml$.

Generation of antibody-secreting hybridomas

After 2 weeks the EBV-transformed B lymphocytes were fused with a mouse plasmacytoma cell line according to the method described before [29]. In brief, the fusions were performed with transformed B lymphocytes and the mouse plasmacytoma OURI in the ratio 1:1 in the presence of polyethylene glycol 45% (Sigma) in PBS. The fusion products were suspended in a DMEM culture medium $+10\%$ FCS supplemented with hypoxanthine/ aminopterin/thymidine (HAT; Sigma) at dilution of 1:50 and Ouabain at 1μ M.

ELISA and cloning

The supernatants from cell lines obtained from the fusions were screened after 2 weeks by ELISA for IgM and IgA RF activities.

Briefly, 96-well ELISA plates (Maxisorp; Nunc-immuno plate, Roskilde, Denmark) were coated with human IgG $(\gamma$ -kabi; Pharmacia, Uppsala, Sweden) $10 \mu g/ml$ in PBS. Plates were blocked with 1% bovine serum albumin (BSA). Following washing, supernatants were added and the plates were incubated at 37° C for 1–2 h. The plates were washed again and goat anti-human IgM (μ -chain specific) or goat anti-human IgA (α -chain specific) alkaline-phosphatase conjugate (Sigma) were added and incubated at 37° C for 2 h. Finally, the plates were washed as before, and Sigma 104 phosphatase substrate (1 mg/ml in diethanolamine buffer pH 9·8) was added and the absorbance was measured after 20 min at 405 nm. Uncoated trays blocked with BSA were used to eliminate antibodies giving unspecific binding. RF-secreting cell lines were cloned repeatedly by limiting dilution as described before [17].

Positive RF clones were tested in ELISA against Fc fragments of human IgG, rabbit IgG (10 μ g/ml each; Sigma), Fab and F(ab')₂ of human IgG (5 μ g/ml each; Calbiochem-Novabiochem, La Jolla, CA), tetanus toxoid ($5 \mu g/ml$; NBCI, Cambridge, UK), singlestranded DNA (ssDNA) (50 μ g/ml; gift from Professor O. Mellbye, University of Oslo, Norway), and human IgG subclasses $(10 \mu g$ / ml; a gift from Professor T. Michalsen, University of Oslo).

Preparation of mRNA, cDNA and sequencing

Total mRNA was extracted as described previously [12,30] and reverse transcribed to cDNA as described before [12,18]. V_H region genes were amplified by polymerase chain reaction (PCR) using specific V_H leader primers and $c\mu$ constant region primer as before [19,20], except for clones RF SN2, RF SN4 and RF VR1 (HY4) leader primer was used (5['] CTGGTGGCAGCTCCCA-GATG $3'$) and for RF EF2 (HY1) leader primer was used $(5'$ GCTCCAGGTGCCCACTCCCA 3') and for RF SN1 (HM3R) (5' TCGGACCGTATCCGACGGG GAATTCTCACA 3') constant region primer was used. The PCR products were gel purified and directly sequenced in both directions [14] using the same primers as for PCR. The closest GL genes were identified by search in the V BASE and DNAPLOT sequence directory (I. Tomlinson, H. H. Althaus *et al*., MRC Centre for Protein Engineering, Cambridge, UK, and University of Cologne, Germany).

Statistical analysis

Mann–Whitney *U*-test was used to analyse the differences between the mean numbers of mutations of the three groups of

None of the clones showed any reactivity with tetanus toxoid or ssDNA.

q 1999 Blackwell Science Ltd, *Clinical and Experimental Immunology*, **117**:388–394

RF (pSS, RA, and HID). Fisher's exact test was used to analyse the differences between R:S ratios in the CDRs for the whole panels of RF from pSS, RA and HID. Differences were considered significant at two-sided *P* values < 0·05.

RESULTS

Specificity of monoclonal RF autoantibodies

We have derived 10 IgM RF clones monospecific for the Fc region of human IgG from six different patients with pSS (Table 1). Five of the clones (50%) were also found to be reactive with rabbit IgG (RF MA1, RF UL1, RF VR1, RF EF2, RF SN5). Five clones (RF EF1, RF EF2, RF SN1, RF SN5, RF LM1) showed pan specificity (reactive to all human IgG subclasses), while four clones (RF MA1, RF UL1, RF SN2, RF VR1) showed the classical Ga specificity (reactive with IgG1, IgG2 and IgG4 but not IgG3). One clone (RF SN4) was found only reactive with IgG1. None of the 10 clones was reactive with Fab, $F(ab')_2$, tetanus toxoid, or ssDNA.

V gene sequence analysis

The sequences of the heavy chains (Table 2 and Fig. 1) revealed that four of the clones (40%) were encoded by V_H 4 family genes (RF SN2, RF SN4, RF VR1, RF EF1), four (40%) used V_H1 family genes (RF MA1, RF UL1, RF EF1, RF SN1), one used a V_H 3 gene (RF LM1) and one clone used a V_H2 gene (RF SN5). All of the V_H genes used have been described before in RF from either RA patients or HID [21–23]. Of the V_H1 family clones, one of them (RF MA1) was closest to DP-10 GL gene, RF UL1 was highly homologous to DP-88 GL gene, RF EF2 used DP-14 GL and RF SN2 used DP-7. Interestingly, three of the four V_H4 clones were closest to the GL gene DP-79 and all three rearranged to the J_H4b segment. Two of these were from one patient (RF SN2 and RF SN4) and one from a different patient (RF VR1). The fourth V_H4 clone (RF EF1) used DP-65 GL gene. The V_H3 clone (RF LM1) had closest homology to the DP-46 GL gene and the V_H2 clone was closest to the DP-26 GL gene. All of the clones were rearranged to different D-segments (Fig. 2) except two pairs. RF SN4 and RF EF1 used the D3–22 segment in two different reading frames and RF SN2, RF SN5 used the D1-26 segment also in two different reading frames. Analysis of the J segments showed that J_H6 was preferentially used, four clones rearranged to the $J_H 6b$ segment (RF UL1, RF EF2, RF SN1, RF LM1), while the fifth clone (RF MA1) rearranged to the J_H 6c segment (RF MA1). Four clones rearranged to J_H4b (RF SN5, RF SN2, RF SN4, RF VR1), and only one clone used the J_H5b segment (RF EF1).

Analysis of the mutational patterns

In contrast to what has been found in RF from RA and HID, most of the present clones were found to be highly homologous to their closest GL gene. Surprisingly, four of the clones were found to be unmutated copies of their closest GL genes at the nucleotide level. Three of them used V_H4 family genes (RF VR1, RF SN2 and RF EF1), while the fourth used a V_H1 family gene (RF SG1) (Table 3). Two other clones had only one silent mutation (RF EF2 and RF SN5). Thus six clones were 100% homologous to the GL product at the amino acid level. One clone had three mutations (RF UL1); two replacement mutations in the CDR_H1 and one silent mutation in framework two. Only three clones were moderately to highly mutated comparable to that seen in RF of RA and HID (RF MA1, RF SN4, RF LM1 had six, 11, and 14 mutations per V_H

Table 2. Monoclonal IgM rheumatoid factor (RF) from pSS patients are shown with family gene, the closest identified V_H , D and J_H germ-line (GL) gene segment, and the length (L) of CDR_H3 amino acid sequence

Clone $\rm V_H$		$V_H GL$	D	J_{H}	L CDR $3H$	
RF MA1	1	$1-69$ (DP-10)	$D21-9$	J_H 6c	11	
RF UL1	1	$1-e$ (DP-88)	DN ₄	$J_H 6b$	13	
RF EF2	1	$1-18$ (DP-14)	DN ₁	$J_H 6b$	19	
RF SN1	1	$1-46$ (DP-7)	$D4 - 17$	$J_H 6b$	13	
RF SN5	\overline{c}	$2-26$ (DP-26)	$D1 - 26$	$J_H 4b$	13	
RF LM1	3	$3-30.3$ (DP-46)	$D4-h$	$J_H 6b$	21	
RF SN ₂	4	$4-39$ (DP-79)	$D1 - 26$	$J_H 4b$	16	
RF SN4	4	$4-39$ (DP-79)	$D3 - 22$	$J_H 4b$	13	
RF VR1	4	$4-39$ (DP-79)	$D6-19$	$J_H 4b$	11	
RF EF1	4	$4-31$ (DP-65)	$D3 - 22$	$J_H 5b$	10	

gene, respectively). All three had from two to five replacement mutations in the CDR regions. The mean number of mutations was 3.6 per V_H gene. This is statistically significantly lower than the mean numbers for RA RF (mean 11 and $P = 0.0028$, Mann– Whitney *U*-test) and HID RF (mean 10 and $P = 0.0051$) [11,22]. The R:S ratio for $CDR_H1 + 2$ for RF in pSS was 2.5 (Table 3), which is not statistically different from the ratios found in RA or HID RF.

DISCUSSION

RF are autoantibodies against antigenic determinants on the Fc region of human IgG, but many RF are also reactive to IgG of other species, e.g. rabbit IgG [4,17]. Our pSS RF satisfy these criteria. In addition, the majority showed the pan and Ga classical specificity similar to RA RF [17,31].

In humans, V_H 3 family genes are the most frequent family used by antibodies (50–60%) [32–34]. This is also true for RF from RA, where V_H 3 has been found to be the most frequent family (60– 80%) followed by V_H1 and V_H4 [35–37]. However, if RF only derived from blood of RA are considered, V_H1 is the predominant family (50%), followed by V_H4 (25%) and V_H3 (25%) [38–40]. This is similar to RF derived from the peripheral blood of HID (53.4% used V_H1, 37.9% used V_H3, and 5.2% used V_H4) [12,14]. In pSS RF only one clone used V_H3, whereas V_H1 and V_H4 were equally represented (40% each). This looks closer to RF derived from the blood of both RA patients and normals, but clearly different from the distribution found in the synovial tissues of RA patients. This finding is supported by idiotype studies done previously, where elevated levels of V_H1 -associated cross-reactive idiotype in the sera from patients with pSS were found [36,41,42]. In addition, our panel also showed a high degree of heterogeneity with eight different GL genes encoding 10 RF clones. This is comparable to RF from RA and HID, which also showed a large degree of heterogeneity. All GL genes utilized by pSS RF were seen previously in RA and/or HID RF. Two GL genes each, used once by our clones (V_H1 DP-10 and V_H2 DP-26) were seen before in both RA and HID RF; DP-10 was used by several clones from HID, RA, and MC RF [33,43], while DP-26 was used before by two clones from HID and one RF clone from RA synovium [12].

The most frequent GL used by our clones was DP-79 (30%) and this was found to be used by several RF clones from both synovium and peripheral blood of RA but not of HID [22,23].

q 1999 Blackwell Science Ltd, *Clinical and Experimental Immunology*, **117**:388–394

Fig. 1. Amino acid sequences of the V_H gene region of IgM rheumatoid factor (RF) from pSS. Closest identified germ-line genes in the V BASE and DNAPLOT are shown. Dashes denote
homology, uppercase letters denote replacem **Fig. 1.** Amino acid sequences of the V_H gene region of IgM rheumatoid factor (RF) from pSS. Closest identified germ-line genes in the V BASE and DNAPLOT are shown. Dashes denote homology, uppercase letters denote replacement mutation, whereas lower case letters denote silent mutation. The codons are numbered according to the definition of Kabat [51].

Fig. 2. Nucleotide sequences of D segment of pSS rheumatoid factors (RF) compared with the closet germ-line (GL) D segment. Upper case denotes mismatches with the GL.

Interestingly, all our DP-79 clones rearranged to the J_H4 segment which was similar to most DP-79 RF clones from RA which also used the J_H4 segment. This suggests that a combination of V_H DP-79 and J_H 4 might be important in RF specificity. The other GL genes used by our clones, and also seen before in RA RF, were DP-46, which were similarly used by two clones from RA synovium [22]. DP-14 and DP-7 were each used by one RF clone from RA synovium [22,23]. DP-88 and DP-65 GL genes were used by RF from HID and pSS but not from RA [12,22]. Although the frequency of V_H family use was different, in general the GL gene usage of pSS RF seemed more similar to RA RF than HID RF.

Table 3. Total number of mutations, R:S ratios of $CDR_H1 + 2$ and $FR_H1 + 2 + 3$ of the V_H segment of IgM rheumatoid factor (RF) of pSS in different V_H families and the overall panel of IgM pSS RF

	Clone	$CDR1+2$			$FR1 + 2 + 3$			
V_H		R	S	CDRs R: S	R	S	FRs R: S	Total
V_H1	RF MA1	1	1	1	\overline{c}	2	1	6
	RF UL1	\mathfrak{D}	Ω		θ	1		3
	RF EF2	Ω	1		Ω	Ω		1
	RF SN1	θ	Ω		θ	Ω		Ω
	Total V_H1	3	\overline{c}	1.5	\overline{c}	3	0.67	10
V_H2	RF SN5	Ω	Ω		$\overline{0}$	1		
V_H 3	RF LM1	5	1	5	5	3	1.67	14
V_H4	RF VR1	Ω	Ω		Ω	Ω		0
	RF SN ₂	Ω	Ω		θ	Ω		0
	RF SN4	\mathfrak{D}	1	2	5	3	1.67	11
	RF EF1	Ω	Ω		Ω	Ω		Ω
	Total V_H4	\mathfrak{D}	1	$\mathcal{D}_{\mathcal{L}}$	$\overline{}$	3	1.67	11
	Total	10	$\overline{4}$	2.5	12	10	$1-2$	36

A striking finding is the preferential use of the J_H6 segment (50%). Generally J_H4 is the most frequent J segment used (45– 65%), followed by J_H6 (about 20–25%) [44,45], and this was also true for RA and HID where J_H 4 is the most frequently used by RF [22]. This might be due to selective activation of B cells clones. D-segment use was diverse.

It has been postulated that the generation of autoantibodies can occur mainly through either an antigen-driven response [35], as in RA and HID RF, or through other mechanisms such as unspecific polyclonal or monoclonal activation. In the former mechanism the B cell undergoes a germinal centre reaction where the immunoglobulin V regions undergo a process of somatic hypermutation, affinity maturation and selection [35]. Clonal expansion and class switch have been seen in RF from RA. Following polyclonal and monoclonal activation the antibodies generated have low affinity and they are very close or directly encoded by the GL, as in MC RF.

The majority of pSS RF were 100% homologous to a GL gene product (six out of 10); to our knowledge only one RF clone out of 55 from RA synovium and only one out of 34 from HID were encoded directly by the GL [12,22,23,25]. Three of our pSS RF clones had a substantial number of mutations [11,29]. In the first one (RF LM1) there was evidence of targeting the replacement mutation in the CDR5 regions ($R: S = 1 + 2$); and this indicates that this RF had been selected during the germinal centre reaction. The second clone (RF SN4) had 11 mutations, but most of those mutations were in FR regions (eight mutations), while the third clone (RF MA1) had only one replacement and one silent mutation in CDR $_H$ 1 and the rest in FR $_H$ 3. This indicates that there was no pressure in the CDR region of these two clones but they had still undergone a germinal centre process.

Our data suggest that there is little or no role for somatic mutation in the generation of most RF in pSS. This has been suggested indirectly by previous studies with idiotype markers $[34,36,37,41-43,46-48]$. One explanation for this is that there may be intrinsic B cell defects resulting in failure to diversify the GL by somatic mutations [46]. The possible mechanism of generation of those antibodies is through unspecific polyclonal activation and expansion of B cells without an antigen-driven process and T cell help. This could be part of the immunological and pathological processes acting in SS, as indicated by the considerable number of SS patients who develop hypergammaglobulinaemia and lymphoma and monoclonal gammopathy due to monoclonal B cell activation and production of MC RF.

However, Stott *et al*. and Bahler & Swerdlow studied rearranged variable region genes without defined antibody specificities within the labial salivary glands from patients with SS and showed evidence of antigen-driven germinal centre response [49,50]. These findings suggest that our RF from peripheral blood of pSS might not be involved in the local pathology of the disease.

In conclusion, our data suggest that there is very little role for somatic mutation in the generation of RF from peripheral blood in pSS.

ACKNOWLEDGMENTS

This study was supported by European Biomed concerted action BMH4- CT96-0595, the Research Council of Norway, Medinnova Foundation. We gratefully acknowledge the excellent technical help of Eilen Strand, Ingvild Vatan, and Lill Næss. We sincerely thank Professor Ove Mellby for provision of ssDNA, Professor Terje Michalsen for provision of IgG subclasses and Dr Eva Källberg for valuable discussion and advice.

q 1999 Blackwell Science Ltd, *Clinical and Experimental Immunology*, **117**:388–394

REFERENCES

- 1 Tzioufas AG, Talal N, Moutsopoulos HM. Sjögren's syndrome: from polyclonal B cell activation to monoclonal B cell proliferation. In: Panayi GS, Whaley K, eds. Immunology of connective tissue diseases. Dordrecht: Kluwer Academic, 1994:335–54.
- 2 Lane HC, Fauci AS. Sjögren's syndrome. In: Wilson JD, Braunwald E, Isselbacher KJ *et al.*, eds. Harrison's principles of internal medicine. New York: McGraw-Hill, 1991:1449–50.
- 3 Tzioufas AG, Moutsopoulos HM. Sjögren's syndrome. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby, 1998:7.32.1–12.
- 4 Børretzen M, Mellbye OJ, Thompson KM, Natvig JB. Rheumatoid factors. In: Peter JB, Shoenfeld Y, eds. Autoantibodies. Amsterdam: Elsiver Science B.V., 1996:706–15.
- 5 Markusse HM, Otten HG, Vroom TM, Smeets TJ, Fokkens N, Breedveld FC. Rheumatoid factor isotypes in serum and salivary fluid of patients with primary Sjögren's syndrome. Clin Immunol Immunopathol 1993; **66**:26–32.
- 6 Atkinson JC, Fox PC, Travis WD *et al.* IgA rheumatoid factor and IgA containing immune complexes in primary Sjögren's syndrome. J Rheumatol 1989; **16**:1205–10.
- 7 Zvaifler NJ. The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol 1973; **16**:265–336.
- 8 Fehr K, Zelvart M, Rauber M, Knopef M, Baici A, Salagam P, Boni A. Production of agglutinators and rheumatoid factors in plasma cells of rheumatoid and non-rheumatoid synovial tissues. Arthritis Rheum 1981; **24**:510–9.
- 9 Kalsi J, Isenberg D. Rheumatoid factor: primary or secondary event in the pathogenesis of RA? Int Arch Allergy Immunol 1993; **102**:209– 15.
- 10 Heyman B. Fc-dependent IgG mediated suppression of the antibody response: fact or artefact? Scand J Immunol 1990; **31**:601–7.
- 11 Posnett DN, Edinger J. When do microbes stimulate rheumatoid factor? J Exp Med 1997; **185**:1721–3.
- 12 Børrezten M, Natvig JB, Thompson KM. Hetrogenous RF structures between and within healthy individuals are not related to HLA-DRB1*0401. Mol Immmunol 1997; **34**:929–38.
- 13 Djavad N, Bas S, Shi X, Schwager J, Jeannet M, Vischer T, Roosnek E. Comparison of rheumatoid factors of rheumatoid arthritis patients, of individual with mycobacterial infections and of normal controls: evidence for maturation in the absence of an autoimmune response. Eur J Immunol 1996; **26**:2480–6.
- 14 Thompson KM, Randen I, Børretzen M, Førre Ø, Natvig JB. Variable region gene usage of human monoclonal rheumatoid factors derived from healthy donors following immunization. Eur J Immunol 1994; **24**:1771–8.
- 15 Randen I, Brown D, Thompson KM *et al.* Clonally related IgM rheumatoid factors undergo affinity maturation in the synovial tissue. J Immunol 1992; **148**:3296–301.
- 16 Randen I, Thompson KM, Thorpe S, Førre Ø, Natvig JB. Human monoclonal IgG rheumatoid factors from the synovial tissue of patients with rheumatoid arthritis. Scand J Immunol 1993; **37**:668–72.
- 17 Randen I, Thompson KM, Natvig JB, Førre Ø, Waalen K. Human monoclonal rheumatoid factors derived from the polyclonal repertoire of rheumatoid synovial tissue: production and characterization. Clin Exp Immunol 1989; **78**:13–18.
- 18 Børretzen M, Randen I, Zdarsky E, Førre Ø, Natvig JB, Thompson KM. Control of antibody affinity by selection against amino acid replacements in the complementary determining regions. Proc Natl Acad Sci USA 1994; **91**:12917–21.
- 19 Pascual V, Randen I, Thompson K, Sioud M, Førre Ø, Natvig J, Capra JD. The complete nucleotide sequences of the heavy chain variable regions of six monospecific rheumatoid factors derived from Epstein Barr virus-transformed B cells isolated from the synovial tissue of patients with rheumatoid arthritis. Further evidence that some autoantibodies are unmutated copies of germline genes. J Clin Invest 1990; **86**:1320–8.
- 20 Pascual V, Victor K, Randen I *et al.* Nucleotide sequence analysis of rheumatoid factors and polyreactive antibodies derived from patients with rheumatoid arthritis reveals diverse use of V_H and V_L gene segments and extensive variability in CDR-3. Scand J Immunol 1992; **36**:349–62.
- 21 Børrezten M, Randen I, Natvig JB, Thompson KM. Structural restriction in the heavy chain CDR3 of human rheumatoid factors. J Immunol 1995; **155**:3630–7.
- 22 Børrezten M, Chapman C, Natvig JB, Thompson KM. Differences in mutational patterns between rheumatoid factors in health and disease are related to variable heavy chain family and germline gene usage. Eur J Immunol 1997; **27**:735–41.
- 23 Ermel RW, Kenny TP, Wong A, Chen PP, Malyj W, Robbins DL. Analysis of the molecular basis of synovial rheumatoid factors in rheumatoid arthritis. Clin Immunol Immunopathol 1997; **84**:307–17.
- 24 Thompson KM, Randen I, Natvig JB, Mageed RA, Jefferis R, Carson DA, Tighe H, Førre Ø. Human monoclonal rheumatoid factors derived from the polyclonal repertoire of rheumatoid synovial tissue: incidence of cross-reactive idiotopes and expression of V_H and V kappa subgroups. Eur J Immunol 1990; **20**:863–8.
- 25 Jain RI, Fais F, Kaplan S *et al.* Ig H and L chain variable region gene sequence analysis of twelve synovial tissue-derived B cell lines producing IgA, IgG, and IgM rheumatoid factors structure/function comparisons of antigenic specificity, V gene sequence, and IG isotype. Autoimmunity 1995; **22**:229–43.
- 26 Stüber F, Lee SK, Bridges SL Jr, Koopman WJ, Schroeder HW Jr, Gaskin F, Fu SM. A rheumatoid factor from a normal individual encoded by V_H2 and V_KII gene segments. Arthritis Rheum 1992; 35:900–4.
- 27 Vitali C, Bombardieri S, Moutsopoulos HM *et al.* Preliminary criteria for the classification of Sjögren's syndrome. Results of an EEC prospective concerted action. Arthritis Rheum 1993; **36**:340–7.
- 28 Kjeldsen-Kragh J, Mellbye OJ, Haugen M, Mollnes TE, Hammer HB, Sioud M, Førre Ø. Changes in laboratory variables in rheumatoid arthritis patients during a trial of fasting and one-year vegetarian diet. Scand J Rheumatol 1995; **24**:85–93.
- 29 Thompson KM, Hough DW, Maddison PJ, Melamed MD, Hughes JN. The efficient production of stable human monoclonal antibody secreting hybridomas from EBV transformed lymphocytes using the mouse myeloma X63-Ag8.653 as fusion partner. J Immunol Methods 1986; **94**:7–12.
- 30 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; **162**:156–9.
- 31 Gaarder PI, Natvig JB. Hidden rheumatoid factors reacting with 'Non a' and other antigens of native autologus IgG. J Immunol 1970; **105**: 928–37.
- 32 Guigou V, Cuisinier AM, Tonnelle C, Moinier D, Fougereau M, Fumoux F. Human immunoglobulin VH and VK repertoire revealed by in situ hybridization. Mol Immunol 1990; **27**:935–40.
- 33 Zouali M, Theze J. Probing VH gene-family utilization in human peripheral B cells by in situ hybridization. J Immunol 1991; **146**: 2855–64.
- 34 Shokri F, Mageed RA, Maziak BR, Jefferis R, Expression of VHIIIassociated cross-reactive idiotypes on human B-lymphocytes: association with staphylococcal protein A (SPA) binding and staphylococcus aureus Cowan I (SAC) stimulation. J Immunol 1991; **146**:936–40.
- 35 Randen I, Thompson KM, Natvig JB *et al.* Rheumatoid factor V genes from patients with rheumatoid arthritis are diverse and show evidence of antigen driven response. Immunol Rev 1992; **128**:49–71.
- 36 Shokri F, Mageed RA, Kitas GD, Katsikis P, Moutsopoulos HM, Jefferis R. Quantification of cross-reactive idiotype-positive rheumatoid factor produced in autoimmune rheumatic diseases. An indicator of clonality and B cell proliferative mechanisms. Clin Exp Immunol 1991; **85**:20–27.
- 37 Melero J, Aguilera I, Mageed RA, Jefferis R, Tarragó D, Núòez-Roldán A, Sa´nchez B. The frequent expansion of a subpopulation of B cells that express RF-associated cross reactive idiotypes: evidence from analysis
- q 1999 Blackwell Science Ltd, *Clinical and Experimental Immunology*, **117**:388–394

of a panel of autoreactive monoclonal antibodies. Scand J Immunol 1998; **48**:152–8.

- 38 Harindranath N, Goldfarb IS, Ikematsu H, Burastero SE, Wilder RL, Notkins AL, Casali P. Complete sequence of the genes encoding the V_H and V_L regions of low and high affinity monoclonal IgM and IgA1 rheumatoid factors produced by $CD5⁺$ B cells from a rheumatoid arthritis patient. Int Immunol 1991; **3**:1188–99.
- 39 Youngblood K, Fruchter L, Ding G, Lopez J, Bonagura V, Davidson A. Rheumatoid factors from the peripheral blood of two patients with rheumatoid arthritis are genetically heterogeneous and somatically mutated. J Clin Invest 1994; **93**:852–61.
- 40 Mantovani L, Wilder RL, Casali P. Human rheumatoid B-1a $(CD5⁺ B)$ cells make hypermutated high affinity IgM rheumatoid factors. J Immunol 1993; **151**:473–88.
- 41 Shokri F, Mageed RA, Maziak BR, Talal N, Amos N, William BD, Jefferis R. Lymphoproliferation in primary Sjögren's syndromeevidence of selective expansion of a B cell subset characterized by the expression of cross reactive idiotypes. Arthritis Rheum 1993; **36**:1128–36.
- 42 Shokri F, Mageed RA, Kitas GD, Moutsopoulos HM, Jefferis R. The level of rheumatoid factor associated cross-reactive idiotypes in Sjögren's syndrome, rheumatoid arthritis, SLE and healthy individuals (abstract). Br J Rheumatol 1989; **28** (Suppl. 1):40.
- 43 Shimizu S, Sugai S, Imaoka T, Sawada M, Konda S. Monoclonal antiidiotypic antibodies against monoclonal rheumatoid factors derived from patients with Sjögren's syndrome. Scand J Rheumatol 1986; Suppl. 61:106–10.
- 44 Sanz I. Multiple mechanism participate in the generation of diversity of human H chain CDR3 regions. J Immunol 1991; **147**:1720–9.
- 45 Yamada M, Wasserman R, Reichard BA, Shane S, Caton AJ, Rovera G. Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes. J Exp Med 1991; **173**:395–407.
- 46 Fox RI, Chen P, Carson DA, Fong S. Expression of cross-reactive idiotype on rheumatoid factor in patients with Sjögren's syndrome. J Immunol 1986; **136**:477–83.
- 47 Sugai S, Saito I, Masaki Y, Takeshita S, Shimizu S, Tachibana J, Miyasaka N. Rearrangement of the rheumatoid factor related germline gene *V*g and bcl-2 expression in lymphoproliferative disorders in patients with Sjögren's syndrome. Clin Immunol Immunopathol 1994; 72:181-6.
- 48 Deacon EM, Mathews JB, Potts AJ, Hamburger J, Mageed RA. Expression of rheumatoid factor associated cross reactive idiotopes by glandular B cells in Sjögren's syndrome. Clin Exp Immunol 1991; **83**:280–5.
- 49 Stott DI, Hlepe F, Hummel M, Steinhauser G, Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome. J Clin Invest 1998; **102**:938–46.
- 50 Bahler DW, Swerdlow SH. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjögren's syndrome) begin as nonmalignant antigen-selected expansions. Blood 1998; **91**:1864–72.
- 51 Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. Bethesda: NIH Publication, 1991: no. 91–3243.